Psoriasis: An evidence-based update. Report of the 9th Evidenced Based Update Meeting, 12 May 2011, Loughborough, U.K.

British Journal of Dermatology

Volumn 166, Issue 2, 2012, Pages 252-260

  De Mozzi, P ^a   Johnston, G A ^a   Alexandroff, A B ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; BETAMETHASONE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; COAL TAR; CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE 17,21 DIPROPIONATE; DITHRANOL; ETANERCEPT; ETRETIN; ETRETINATE; FLUOROURACIL; FUMARIC ACID; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; PSORALEN; SALICYLIC ACID; STEROID; TAZAROTENE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB; VITAMIN D DERIVATIVE;

BLISTER; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DRUG WITHDRAWAL; ECZEMA; EVIDENCE BASED MEDICINE; HAIR DISEASE; HUMAN; MEDICAL SOCIETY; NAIL DISEASE; NAIL PSORIASIS; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUSTULAR PSORIASIS; PUSTULOSIS PALMOPLANTARIS; SCALP HAIR; SKIN ATROPHY; SKIN CANCER; SKIN DISEASE; SKIN INFECTION; SKIN IRRITATION; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; URTICARIA;

ADMINISTRATION, CUTANEOUS; BIOLOGICAL AGENTS; COMBINED MODALITY THERAPY; DERMATOLOGIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; NAIL DISEASES; PSORIASIS; PUVA THERAPY; SCALP DERMATOSES;

EID: 84856168198     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10767.x     Document Type: Conference Paper

References (163)

1. Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2009; 2: CD005028.
2. Hofer A, Fink-Puches R, Kerl H, et al. Comparison of phototherapy with near vs. far erythemogenic doses of narrow-band ultraviolet B in patients with psoriasis. Br J Dermatol 1998; 138: 96-100.
3. Inzinger M, Heschl B, Weger W, et al. Efficacy of PUVA therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. Br J Dermatol 2011; 165: 640-5.
4. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): 1-70.
5. Wolf P, Hofer A, Legat FJ, et al. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol 2009; 160: 186-9.
6. Ortonne JP, Khemis A, Koo JY, et al. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2005; 19: 556-63.
7. Legat FJ, Hofer A, Wackernagel A, et al. Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. Arch Dermatol 2007; 143: 1016-22.
8. Kircik L, Bagel J, Korman N, et al. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 2008; 7: 245-53.
9. Weger W, Hofer A, Legat FJ, et al. UVB-311 nm advances the clearance of psoriatic lesions in ustekinumab-treated patients. J Invest Dermatol 2010; 130: S48.
10. Wolf P, Hofer A, Weger W, et al. 311 nm UVB accelerated response of psoriatic lesions in adalimumab-treated patients. Photodermatol Photoimmunol Photomed 2011; 27: 186-9.
11. Zane C, Capezzera R, Venturini M, et al. A short cycle of narrow-band UVB phototherapy in the early phase of long-term efalizumab can provide a quicker remission of moderate and severe psoriasis: a pilot study. Dermatology 2009; 218: 321-6.
12. Gambichler T, Tigges C, Scola N, et al. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks. Br J Dermatol 2011; 164: 1383-6.
13. Di Lernia V, Albertini G,. Is antitumour necrosis factor therapy combined with ultraviolet B phototherapy safe? Br J Dermatol 2010; 162: 1147-8.
14. Michaelsson G, Kristjansson G, Pihl Lundin I, et al. Palmoplantar pustulosis and gluten sensitivity: a study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten-free diet. Br J Dermatol 2007; 156: 659-66.
15. Michaelsson G, Gustafsson K, Hagforsen E,. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol 2006; 54: 737-8.
16. Abdul GS, Finlay AY,. Moral and cost dilemma of a psoriasis patient. Br J Dermatol 2007; 156: 186-7.
17. Ono T, Jono M, Kito M, et al. Evaluation of tonsillectomy as a treatment for pustulosis palmaris et plantaris. Acta Otolaryngol Suppl 1983; 401: 12-16.
18. Ono T,. Evaluation of tonsillectomy as a treatment for pustulosis palmaris et plantaris. J Dermatol 1977; 4: 163-72.
19. Murray D, Warin AP,. Photochemotherapy for persistent palmoplantar pustulosis (PPP). Br J Dermatol 1979; 101 (Suppl. 17): 13-14.
20. Murray D, Corbett MF, Warin AP,. A controlled trial of photochemotherapy for persistent palmoplantar pustulosis. Br J Dermatol 1980; 102: 659-63.
21. Lawrence CM, Marks J, Parker S, et al. A comparison of PUVA-etretinate and PUVA-placebo for palmoplantar pustular psoriasis. Br J Dermatol 1984; 110: 221-6.
22. Lassus A, Lauharanta J, Eskelinen A,. The effect of etretinate compared with different regimens of PUVA in the treatment of persistent palmoplantar pustulosis. Br J Dermatol 1985; 112: 455-9.
23. Kolbach DN, Nieboer C,. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol 1992; 27: 769-71.
24. Altmeyer PJ, Matthes U, Pawlak F, et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994; 30: 977-81.
25. Nieboer C, de Hoop D, Langendijk PN, et al. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica 1990; 181: 33-7.
26. Stander H, Stadelmann A, Luger T, et al. Efficacy of fumaric acid ester monotherapy in psoriasis pustulosa palmoplantaris. Br J Dermatol 2003; 149: 220-2.
27. Gerdes S, Franke J, Domm S, et al. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol 2010; 163: 1116-18.
28. Mrowietz U, van de Kerkhof PC,. Management of palmoplantar pustulosis: do we need to change? Br J Dermatol 2011; 164: 942-6.
29. de Vries ACQ, Bogaards NA, Hooft L, et al,. Interventions for nail psoriasis: a Cochrane review. Presented at the 20th European Academy of Dermatology and Venereology Congress, 20-24 October 2011, Lisbon.
30. de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1728 patients. Dermatology 1996; 193: 300-3.
31. Augustin M, Reich K, Blome C, et al. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 2010; 163: 580-5.
32. Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58: 224-31.
33. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60: 976-86.
34. Yu RC, King CM,. A double-blind study of superficial radiotherapy in psoriatic nail dystrophy. Acta Derm Venereol 1992; 72: 134-6.
35. Cannavo SP, Guarneri F, Vaccaro M, et al. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology 2003; 206: 153-6.
36. de Jong EM, Menke HE, van Praag MC, et al. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study. Dermatology 1999; 199: 313-18.
37. Rigopoulos D, Gregoriou S, Katsambas A,. Treatment of psoriatic nails with tazarotene cream 0·1% vs. clobetasol propionate 0·05% cream: a double-blind study. Acta Derm Venereol 2007; 87: 167-8.
38. Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol 2008; 88: 279-80.
39. Kwang TY, Nee TS, Seng KT,. A therapeutic study of nail psoriasis using electron beams. Acta Derm Venereol 1995; 75: 90.
40. Levell NJ, Shuster S, Munro CS, et al. Remission of ordinary psoriasis following a short clearance course of cyclosporin. Acta Derm Venereol 1995; 75: 65-9.
41. Mahrle G, Schulze HJ, Farber L, et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32: 78-88.
42. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009; 461: 747-53.
43. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med 2009; 361: 496-509.
44. Di Cesare A, Di Meglio P, Nestle FO,. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009; 129: 1339-50.
45. Huffmeier U, Lascorz J, Bohm B, et al. Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol 2009; 129: 355-8.
46. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580-92.
47. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
48. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.
49. Ortonne JP, Taieb A, Ormerod AD, et al. Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. Br J Dermatol 2009; 161: 1190-5.
50. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
51. Greaves MW, Weinstein GD,. Treatment of psoriasis. N Engl J Med 1995; 332: 581-8.
52. Driessen RJ, van de Kerkhof PC, de Jong EM,. Daily practice assessment of liver injury in patients with psoriasis on methotrexate. Br J Dermatol 2010; 162: 211-13.
53. Kane S, Ford J, Cohen R, et al. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 2009; 43: 613-16.
54. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005; 60: 800-5.
55. Macbeth AE, Johnston GA,. Twenty-one years of oral retinoid therapy in siblings with nonbullous ichthyosiform erythroderma. Clin Exp Dermatol 2008; 33: 190-1.
56. Ormerod AD, Campalani E, Goodfield MJ,. British Association of Dermatologists' guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 2010; 162: 952-63.
57. Lopez-Lerma I, Iranzo P, Herrero C,. New-onset psoriasis in a patient treated with interferon beta-1a. Br J Dermatol 2009; 160: 716-17.
58. Pink AE, Fonia A, Allen MH, et al. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol 2010; 162: 780-5.
59. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56: 2905-12.
60. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
61. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000-6.
62. Alexandroff AB, Novitskaya ES, Armstrong DJ,. Psoriasis as a multisystem inflammatory disease. In: Advances in Medicine and Biology (, Berhardt LV, ed.), Vol. 6. New York, USA: Nova Science Publishers, 2011; 103-25.
63. Brauchli YB, Jick SS, Miret M, et al. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 2009; 160: 1048-56.
64. Alexandroff AB, Pauriah M, Lang CC, et al. Atherosclerosis as a systemic feature of psoriasis. Clin Exp Dermatol 2011; 36: 451-2.
65. Tobin AM, Kirby B,. Psoriasis: an opportunity to identify cardiovascular risk. Br J Dermatol 2009; 161: 719.
66. Federman DG, Shelling M, Prodanovich S, et al. Psoriasis: an opportunity to identify cardiovascular risk. Br J Dermatol 2009; 160: 1-7.
67. Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586-92.
68. Prodanovich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-7.
69. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493-9.
70. Alexandroff AB, Pauriah M, Camp RD, et al. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009; 161: 1-7.
71. Alexandroff AB, Armstrong DJ,. Psoriasis and psoriatic arthritis: association with other inflammatory diseases and comorbidities. Adv Psor Inflamm Skin Dis 2011; 2: 77-86.
72. Balato N, Di Costanzo L, Balato A, et al. Psoriasis and melanocytic naevi: does the first confer a protective role against melanocyte progression to naevi? Br J Dermatol 2011; 164: 1262-70.
73. Burden AD,. Drug survival rates for tumour necrosis factor-alpha antagonists in psoriasis. Br J Dermatol 2011; 164: 940-1.
74. Warren RB, Kleyn CE, Gulliver WP,. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. Br J Dermatol 2011; 164 (Suppl. 1): 1-14.
75. McAleer MA, Mason DL, Cunningham S, et al. Alcohol misuse in patients with psoriasis: identification and relationship to disease severity and psychological distress. Br J Dermatol 2011; 164: 1256-61.
76. Prasad Hunasehally RY, Anstey AV,. Review of the 90th Annual Meeting of the British Association of Dermatologists, 6-8 July 2010, Manchester, U.K. Br J Dermatol 2011; 164: 712-19.
77. Kallimanis PG, Xenos K, Markantonis SL, et al. Serum levels of transforming growth factor-beta1 in patients with mild psoriasis vulgaris and effect of treatment with biological drugs. Clin Exp Dermatol 2009; 34: 582-6.
78. Dauden E, Santiago-et-Sanchez-Mateos D, Sotomayor-Lopez E, et al. Ustekinumab: effective in a patient with severe recalcitrant generalized pustular psoriasis. Br J Dermatol 2010; 163: 1346-7.
79. Griffiths CE,. Management of psoriasis in pregnancy: time to deliver? Br J Dermatol 2010; 163: 235.
80. Fonia A, Jackson K, Lereun C, et al. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis. Br J Dermatol 2010; 163: 807-16.
81. van Lumig PP, Lecluse LL, Driessen RJ, et al. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol 2010; 163: 838-46.
82. Edwards C, Anstey AV,. Therapeutic ultraviolet light-emitting diode sources: a new phase in the evolution of phototherapy. Br J Dermatol 2010; 163: 3-4.
83. Avramidis G, Kruger-Krasagakis S, Krasagakis K, et al. The role of endothelial cell apoptosis in the effect of etanercept in psoriasis. Br J Dermatol 2010; 163: 928-34.
84. Hackett CB, Kirby B,. Primary varicella-zoster infection in patients on biologic therapies for psoriasis. Br J Dermatol 2010; 163: 1122.
85. Alexandroff AB, Gibbs S,. Skin deep: report from the annual meeting of the British Society for Investigative Dermatology. Exp Oncol 2007; 29: 162-3.
86. Ersser SJ, Cowdell FC, Latter SM, et al. Self-management experiences in adults with mild-moderate psoriasis: an exploratory study and implications for improved support. Br J Dermatol 2010; 163: 1044-9.
87. Cardili RN, Alves TG, Freitas JC, et al. Expression of human leucocyte antigen-G primarily targets affected skin of patients with psoriasis. Br J Dermatol 2010; 163: 769-75.
88. Alexandroff AB, Burd R,. Footprints of the EADV: a meeting report from the 17th Congress of the European Academy of Dermatology and Venereology. Br J Dermatol 2009; 160: 938-45.
89. Dogan S, Atakan N,. Is serum amyloid A protein a better indicator of inflammation in severe psoriasis? Br J Dermatol 2010; 163: 895-6.
90. Woolf RT, Smith CH, Robertson K, et al. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study. Br J Dermatol 2010; 163: 889-92.
91. Bandoli G, Johnson DL, Jones KL, et al. Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. Br J Dermatol 2010; 163: 334-9.
92. Downs AM,. Observational case series on a group of patients with severe psoriasis who failed to respond to antitumour necrosis factor alpha biologics and switched to ustekinumab. Br J Dermatol 2010; 163: 433-4.
93. Alexandroff AB, Graham-Brown RAC,. Report from the 67th Annual Meeting of American Academy of Dermatology. Br J Dermatol 2010; 162: 12-21.
94. Hagforsen E, Hedstrand H, Nyberg F, et al. Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis. Br J Dermatol 2010; 163: 572-9.
95. Langley RG, Strober BE, Gu Y, et al. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol 2010; 162: 1349-58.
96. Zhang K, Hou R, Niu X, et al. Decreased colony formation of high proliferative potential colony-forming cells and granulocyte-macrophage colony-forming units and increased Hes-1 expression in bone marrow mononuclear cells from patients with psoriasis. Br J Dermatol 2010; 163: 93-101.
97. Thaci D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 2010; 163: 402-11.
98. Anstey AV,. Fumaric acid esters in the treatment of psoriasis. Br J Dermatol 2010; 162: 237-8.
99. Alexandroff AB, Johnston GA,. The patient's journey: living with psoriasis-the doctors' perspective. Br J Gen Pract 2010; 60: 141.
100. Soegaard-Madsen L, Johansen C, Iversen L, et al. Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement. Br J Dermatol 2010; 162: 1216-23.
101. Abeyakirthi S, Mowbray M, Bredenkamp N, et al. Arginase is overactive in psoriatic skin. Br J Dermatol 2010; 163: 193-6.
102. Vahavihu K, Ala-Houhala M, Peric M, et al. Narrowband ultraviolet B treatment improves vitamin D balance and alters antimicrobial peptide expression in skin lesions of psoriasis and atopic dermatitis. Br J Dermatol 2010; 163: 321-8.
103. -1) tacalcitol ointment in the treatment of facial psoriasis: an 8-week open-label clinical trial. Br J Dermatol 2010; 162: 1359-64.
104. Hong SP, Oh Y, Jung M, et al. Topical calcitriol restores the impairment of epidermal permeability and antimicrobial barriers induced by corticosteroids. Br J Dermatol 2010; 162: 1251-60.
105. Kemeny L, Csoma Z, Bagdi E, et al. Targeted phototherapy of plaque-type psoriasis using ultraviolet B-light-emitting diodes. Br J Dermatol 2010; 163: 167-73.
106. Yan KX, Fang X, Han L, et al. Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris. Br J Dermatol 2010; 163: 48-56.
107. Santos-Juanes J, Coto-Segura P, Mas-Vidal A, et al. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol 2010; 162: 1144-6.
108. Diluvio L, Romiti ML, Angelini F, et al. Infliximab therapy induces increased polyclonality of CD4+ CD25+ regulatory T cells in psoriasis. Br J Dermatol 2010; 162: 895-7.
109. McFadden JP, Baker BS, Powles AV, et al. Psoriasis and extra domain A fibronectin loops. Br J Dermatol 2010; 163: 5-11.
110. Nosotti L, Francesconi F, Izzi S, et al. Safety of antitumour necrosis factor-alpha therapy in psoriatic patients with hepatitis B virus infection. Br J Dermatol 2010; 162: 1408-10.
111. Yamanaka KI, Kakeda M, Kitagawa H, et al. 1,24-Dihydroxyvitamin D (tacalcitol) prevents skin T-cell infiltration. Br J Dermatol 2010; 162: 1206-15.
112. Driessen RJ, Bisschops LA, Adang EM, et al. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol 2010; 162: 1324-9.
113. Renne J, Schafer V, Werfel T, et al. Interleukin-1 from epithelial cells fosters T cell-dependent skin inflammation. Br J Dermatol 2010; 162: 1198-205.
114. Dawe RS,. Comparing narrowband ultraviolet B treatment regimens for psoriasis. Br J Dermatol 2009; 161: 1215-16.
115. van de Kerkhof PC,. The relevance of biologics for the treatment of patients with psoriasis. Br J Dermatol 2009; 161: 1213-14.
116. Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633-6.
117. Farkas A, Kemeny L,. Psoriasis and alcohol: is cutaneous ethanol one of the missing links? Br J Dermatol 2010; 162: 711-16.
118. Dawe RS,. Using 'number needed to treat' to express the magnitudes of benefit of ultraviolet B phototherapy and of antitumour necrosis factor-alpha therapies for psoriasis. Br J Dermatol 2010; 162: 456-7.
119. Dommasch ED, Shin DB, Troxel AB, et al. Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis. Br J Dermatol 2010; 162: 835-42.
120. Antoniou C, Stefanaki I, Stratigos A, et al. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre. Br J Dermatol 2010; 162: 1117-23.
121. Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010; 162: 137-46.
122. Kamsteeg M, Jansen PA, van Vlijmen-Willems IM, et al. Molecular diagnostics of psoriasis, atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis. Br J Dermatol 2010; 162: 568-78.
123. Naldi L, Svensson A, Zenoni D, et al. Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: update of the EDEN Psoriasis Survey 2001-2006. Br J Dermatol 2010; 162: 384-9.
124. Birkenfeld S, Dreiher J, Weitzman D, et al. Coeliac disease associated with psoriasis. Br J Dermatol 2009; 161: 1331-4.
125. Seidler EM, Kimball AB,. Socioeconomic disability in psoriasis. Br J Dermatol 2009; 161: 1410-12.
126. Seneschal J, Milpied B, Vergier B, et al. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 2009; 161: 1081-8.
127. Brenner M, Molin S, Ruebsam K, et al. Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment. Br J Dermatol 2009; 161: 964-6.
128. Lecluse LL, de Groot M, Bos JD, Spuls PI,. Experience with biologics for psoriasis in daily practice: switching is worth a try. Br J Dermatol 2009; 161: 948-51.
129. Kjellerup RB, Iversen L, Kragballe K, et al. The expression and phosphorylation of eukaryotic initiation factor 4E are increased in lesional psoriatic skin. Br J Dermatol 2009; 161: 1059-66.
130. Laffitte E, Janssens JP, Roux-Lombard P, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol 2009; 161: 797-800.
131. Bangsgaard N, Engkilde K, Thyssen JP, et al. Inverse relationship between contact allergy and psoriasis: results from a patient- and a population-based study. Br J Dermatol 2009; 161: 1119-23.
132. Dubertret L, Chimenti S, Christophers E, et al. Alice, Eloi, Magali and Robert: the lives of four patients with psoriasis and the therapeutic approaches of eight European experts. Br J Dermatol 2009; 161 (Suppl. 2): 1-30.
133. Santos-Briz A, Roncero M, Antunez P, et al. Immunohistochemical expression of cyclin-dependent kinase-2 in psoriasis. Br J Dermatol 2009; 161: 708-10.
134. McFadden JP, Baker BS, Powles AV, et al. Psoriasis and streptococci: postscript regarding extra domain A fibronectin. Br J Dermatol 2009; 161: 706-7.
135. Dominguez PL, Assarpour A, Kuo H, et al. Development and pilot-testing of a psoriasis screening tool. Br J Dermatol 2009; 161: 778-84.
136. Evers AW, Kleinpenning MM, Smits T, et al. Itch and scratching as predictors of time to clearance of psoriasis with narrow-band ultraviolet B therapy. Br J Dermatol 2009; 161: 542-6.
137. Wain EM, Darling MI, Pleass RD, et al. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study. Br J Dermatol 2010; 162: 427-34.
138. Boccardi D, Menni S, La Vecchia C, et al. Overweight and childhood psoriasis. Br J Dermatol 2009; 161: 484-6.
139. Anstey A, George S,. 'Real decisions' on psoriasis care from informed clinicians. Br J Dermatol 2009; 160: 1139.
140. Kleinpenning MM, Smits T, Boezeman J, et al. Narrowband ultraviolet B therapy in psoriasis: randomized double-blind comparison of high-dose and low-dose irradiation regimens. Br J Dermatol 2009; 161: 1351-6.
141. Martin B, Sanchez-Carazo JL, Perez-Ferriols A, et al. Delayed generalized inflammatory psoriasis flare during efalizumab treatment. Br J Dermatol 2009; 161: 212-13.
142. Cheng T, Tjabringa GS, van Vlijmen-Willems IM, et al. The cystatin M/E-controlled pathway of skin barrier formation: expression of its key components in psoriasis and atopic dermatitis. Br J Dermatol 2009; 161: 253-64.
143. Dharamsi JW, Bhosle M, Balkrishnan R, et al. Using 'number needed to treat' to help conceptualize the magnitude of benefit and risk of tumour necrosis factor-alpha inhibitors for patients with severe psoriasis. Br J Dermatol 2009; 161: 605-16.
144. Son SW, Kim EO, Ryu ES, et al. Upregulation of Fas and downregulation of CD94/NKG2A inhibitory receptors on circulating natural killer cells in patients with new-onset psoriasis. Br J Dermatol 2009; 161: 281-8.
145. Verhoeven EW, Kraaimaat FW, de Jong EM, et al. Individual differences in the effect of daily stressors on psoriasis: a prospective study. Br J Dermatol 2009; 161: 295-9.
146. Kragballe K, Hoffmann V, Ortonne JP, et al. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol 2009; 161: 159-66.
147. Lecluse LL, Tutein Nolthenius JL, Bos JD, et al. Patient preferences and satisfaction with systemic therapies for psoriasis: an area to be explored. Br J Dermatol 2009; 160: 1340-3.
148. McFadden JP, Baker BS, Powles AV, et al. Psoriasis and streptococci: the natural selection of psoriasis revisited. Br J Dermatol 2009; 160: 929-37.
149. Rakkhit T, Panko JM, Christensen TE, et al. Plaque thickness and morphology in psoriasis vulgaris associated with therapeutic response. Br J Dermatol 2009; 160: 1083-9.
150. Schmid-Ott G, Jaeger B, Boehm T, et al. Immunological effects of stress in psoriasis. Br J Dermatol 2009; 160: 782-5.
151. Driessen RJ, Boezeman JB, van de Kerkhof PC, et al. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009; 160: 670-5.
152. Smits T, van Laarhoven AI, Staassen A, et al. Induction of protoporphyrin IX by aminolaevulinic acid in actinic keratosis, psoriasis and normal skin: preferential porphyrin enrichment in differentiated cells. Br J Dermatol 2009; 160: 849-57.
153. Sizto S, Bansback N, Feldman SR, et al. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol 2009; 160: 1264-72.
154. Eedy DJ, Griffiths CE, Chalmers RJ, et al. Care of patients with psoriasis: an audit of U.K. services in secondary care. Br J Dermatol 2009; 160: 557-64.
155. Inokuma D, Kodama K, Natsuga K, et al. Autoantibodies against type XVII collagen C-terminal domain in a patient with bullous pemphigoid associated with psoriasis vulgaris. Br J Dermatol 2009; 160: 451-4.
156. Gerdes S, Kurrat W, Mrowietz U,. Serum mast cell tryptase is not a useful marker for disease severity in psoriasis or atopic dermatitis. Br J Dermatol 2009; 160: 736-40.
157. van de Kerkhof PC, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol 2009; 160: 170-6.
158. Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 2009; 160: 319-24.
159. Anderson KS, Wong J, Polyak K, et al. Detection of psoriasin/S100A7 in the sera of patients with psoriasis. Br J Dermatol 2009; 160: 325-32.
160. Warren RB, Smith RL, Campalani E, et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 2009; 160: 438-41.
161. Perlmutter A, Mittal A, Menter A,. Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 2009; 160: 8-15.
162. Henno A, Blacher S, Lambert C, et al. Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis. Br J Dermatol 2009; 160: 581-90.
163. Stenderup K, Rosada C, Worsaae A, et al. Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol 2009; 160: 284-96.